

## tremelimumab

Drug Name	Form	Strength	Infusion Center Available	Restricted	Non-formulary	Ambulatory Available	Interchange	REMS
Imjudo	SOLUTION, INTRAVENOUS	20 mg/mL	✓	✓				

VIEW MORE [Antineoplastic Agents](#)

CLASS >>>

○ High Alert Drug : [Policy](#)

### Additional Information and Links

#### Restricted to:

- Service line: Hematology/Oncology
- Formulary location: Outpatient Infusion
- Service location: Outpatient Infusion Center
- Patient population: Adult
- Prior authorization required: Yes
- Restriction/criteria of use (all will apply unless specified):
  - Confirmed unresectable hepatocellular carcinoma (uHCC) and will receive durvalumab in combination with tremelimumab-actl
    - Child-Pugh Score class A
    - ECOG performance status of 0–1
    - No Hepatitis B and Hepatitis C co- infection, or Hepatitis B and Hepatitis D co-infection
    - No hepatic encephalopathy within the past 12 months
    - No GI bleeding within the past 12 months
  - Confirmed untreated metastatic NSCLC and tremelimumab-actl will be part of a regimen including durvalumab and platinum-based chemotherapy regimen.
    - No prior lines of therapy for metastatic NSCLC
    - Absence of EGFR or ALK mutation
    - ECOG performance status of 0–1
    - Indication identified in the NCCN Guidelines with recommendation as category 1 or 2A only